To our community, colleagues and supporters,
LiverWELL CEO Russell Shewan has announced his resignation for family reasons. He will finish his term as CEO on 10 February 2023.
During his tenure, Russell has worked closely with the liver health and hepatitis communities, Departments of Health, stakeholders and the LiverWELL team and Board to develop a new strategic plan. This will strongly position the organisation to continue to support the elimination of hepatitis B and C, as well as addressing liver health issues more broadly in the coming years in areas such as Non-Alcoholic Fatty Liver Disease, in line with wider population health goals.
Under Russell’s leadership, LiverWELL has implemented project management workflows to streamline the business and improve transparency and reporting. A new community consultation committee has also been established, which will ensure LiverWELL continues to be informed by people with lived experience of hepatitis and liver disease.
These achievements have been possible through the dedication and creativity of the staff, the support of the Board, the invaluable effort of people with lived experience, collaborating organisations, researchers, and clinicians.
LiverWELL thanks Russell for the strong advocacy and passion he brought to the role. His clear vision has provided LiverWELL with strong foundations for the future.
Russell is committed to supporting and assisting the transition to a new CEO. Recruitment for a replacement CEO will begin shortly. Enquiries to Fisher Leadership.
President, LiverWELL Board.
For general enquiries please contact email@example.com